Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.15 CHF | +8.33% | +7.20% | +104.87% |
Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.83M | Sales 2023 | 33.56M 37.01M | Capitalization | 128M 141M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.44M | Net income 2023 | -13M -14.33M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.35M | Net cash position 2023 | 12M 13.23M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.77% |
1 day | +2.05% | ||
1 week | +1.07% | ||
Current month | +1.85% | ||
1 month | +5.43% | ||
3 months | +29.41% | ||
6 months | +122.22% | ||
Current year | +89.11% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 7.15 | +8.33% | 272 634 |
24-05-08 | 6.6 | -1.05% | 53,123 |
24-05-07 | 6.67 | +2.14% | 76,961 |
24-05-06 | 6.53 | -2.10% | 61,288 |
24-05-03 | 6.67 | +2.14% | 143,259 |
Delayed Quote Swiss Exchange, May 08, 2024 at 11:31 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+89.11% | 269M | |
+2.97% | 108B | |
+10.21% | 104B | |
+3.20% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- KURN Stock